FRT vs KLRS
FRT (FRT) versus Kalaris Therapeutics, Inc. (KLRS) — a side-by-side from cached financials, not a winner call.
FRT (FRT) common stock.
Kalaris Therapeutics, Inc. (KLRS) is a biotechnology company listed on US.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
KLRS does not have a complete income-statement cache yet.
FRT currently screens at market cap $0. KLRS currently screens at market cap $0.
Not investment advice. Open the FRT and KLRS stock pages for the full models.
Not investment advice.